Floatz logo

LAMOTRIGINE

Bipolar II Disorder, Most Recent Episode Major Depressive

University of British ColumbiaSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

22 Active assets in the Bipolar II Disorder, Most Recent Episode Major Depressive cohort.

Asset / SponsorPhaseRating
Lurasidone
Massachusetts General Hospital
Phase 4BBB
Seroquel®
First Affiliated Hospital of Zhejiang University
Phase 4BB
Valproic Acid
National Cheng-Kung University Hospital
Phase 4BB
VENLOR
Stanley Medical Research Institute
Phase 4BB
Bxcl501
BioXcel Therapeutics Inc
Phase 3BB

View all 37 →

Same molecule, other indications

LAMOTRIGINE is also rated in:

focal epilepsyDormant
BBB
Indicative ·
79 / 100
View asset →
epilepsy with generalized tonic-clonic seizuresDormant
BBB
Indicative ·
75 / 100
View asset →
bipolar disorderDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →